Abstract
End of April 2020, French clinicians observed an increase in cases presenting with paediatric inflammatory multisystem syndrome (PIMS). Nationwide surveillance was set up and demonstrated temporospatial association with the coronavirus disease (COVID-19) epidemic for 156 reported cases as at 17 May: 108 were classified as confirmed (n = 79), probable (n = 16) or possible (n = 13) post-COVID-19 PIMS cases. A continuum of clinical features from Kawasaki-like disease to myocarditis was observed, requiring intensive care in 67% of cases.
Highlights
End of April 2020, French clinicians observed an increase in cases presenting with paediatric inflammatory multisystem syndrome (PIMS)
To investigate this emerging inflammatory disease in children, named paediatric inflammatory multisystem syndrome (PIMS) or multisystem inflammatory syndrome in children (MIS-C), a nationwide surveillance was launched on 30 April, coordinated by the French Public Health Agency and French paediatric scientific societies
A reporting form was developed which included age of the patient, results of either RT-PCR or serology for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), main clinical features (including seritis, attributes of macrophage activation syndrome (MAS), myocarditis or Kawasaki-like disease (KLD)), type of wards (conventional paediatric unit or intermediate/intensive care unit (ICU)) and, for children admitted to ICU, type of care required and if relevant, occurrence of death
Summary
End of April 2020, French clinicians observed an increase in cases presenting with paediatric inflammatory multisystem syndrome (PIMS). Riphagen et al reported eight children displaying characteristics of hyperinflammatory shock, KLD or toxic shock syndrome [1] and an Italian study reported 10 additional children presenting with a KLD [2] To investigate this emerging inflammatory disease in children, named paediatric inflammatory multisystem syndrome (PIMS) or multisystem inflammatory syndrome in children (MIS-C), a nationwide surveillance was launched on 30 April, coordinated by the French Public Health Agency and French paediatric scientific societies. All French paediatric departments were asked to report retrospectively and prospectively all cases of this hyperinflammatory syndrome diagnosed since 1 March to Santé Publique France The objectives of this surveillance were to estimate the burden of PIMS in France, to describe the spatial and temporal dynamics of this emergence in order to investigate its link with the COVID-19 epidemic. Whenever either the PCR or the serology was noted as pending, clinicians were subsequently asked by email to update the questionnaire a few days after initial notification
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
